Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GenOway
  6. Summary
    ALGEN   FR0004053510

GENOWAY

(ALGEN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
4.245(c) 4.16(c) 4.18(c) 4.09(c) 4.05 Last
9 564 10 655 9 444 49 766 9 049 Volume
-0.12% -2.00% +0.48% -2.15% -0.98% Change
More quotes
Estimated financial data (e)
Sales 2019 14,0 M 16,4 M 16,4 M
Net income 2019 -1,04 M -1,22 M -1,22 M
Net Debt 2019 4,93 M 5,78 M 5,78 M
P/E ratio 2019 -
Yield 2019 -
Sales 2020 16,3 M 19,1 M 19,1 M
Net income 2020 -0,69 M -0,81 M -0,81 M
Net Debt 2020 8,05 M 9,44 M 9,44 M
P/E ratio 2020 -
Yield 2020 -
Capitalization 36,5 M 42,8 M 42,8 M
EV / Sales 2019 0,88x
EV / Sales 2020 1,81x
Nbr of Employees 118
Free-Float 80,1%
More Financials
Company
Genoway SA is a France-based company which is specializes in the provision of genetically modified mouse and rat models for biopharmaceutical companies, laboratories and research institutes. The Company offers an array of services which include site specific transgenesis, random insertion based transgenic models, gene overexpression, humanization, gene deletion and gene knock-down (RNA interference). The Company’s... 
More about the company
All news about GENOWAY
05/27GenOway Société anonyme announced that it has received €5.6 million in funding from Nex..
CI
05/05GenOway Société anonyme announced that it expects to receive €5 million in funding from..
CI
04/30Genoway Soci?T? Anonyme Reports Earnings Results for the Full Year Ended December 31, 2..
CI
2020Genoway S.A. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020GenOway S.A. announced that it has received €1.7 million in funding from Eximium SAS, D..
CI
2020GENOWAY : and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnersh..
AQ
2019GENOWAY : The Institut Pasteur and Cellectis extend exclusive license rights by granting g..
PU
2018Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
CI
2018GenOway S.A. acquired AXENIS S.A.S from Institut Pasteur de Lille.
CI
2018GenOway Société Anonyme agreed to acquire AXENIS S.A.S from Institut Pasteur de Lille f..
CI
2016GENOWAY : Conventional KO (constitutive)
PU
2016GENOWAY : A grant for €1.9 million has been awarded under the Eurostars™ programme t..
PU
2015GENOWAY : The 11th ISTT Prize will be jointly awarded to Jennifer Doudna and Emmanuelle Ch..
PU
2014GENOWAY : Genetically Modified Models by CRISPR/Cas9 Nuclease System
PU
More news
News in other languages on GENOWAY
07/20STOCK MARKET PARIS : Le coronavirus contamine à nouveau les indices
07/19GENOWAY : Accélération de la croissance semestrielle à +30%, tirée par la forte progressio..
07/19GENOWAY : Chiffre d'affaires du 1er semestre 2021
05/28EN DIRECT DES MARCHES : Worldline, Scor, Genoway, Salesforce, Crédit Suisse, JD Logistics,..
05/27GENOWAY : succès de l'augmentation de capital de 5,6 ME
More news
Chart GENOWAY
Duration : Period :
genOway Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOWAY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Christian Grenier Chairman & Chief Executive Officer
Benjamin Bruneau Chief Financial Officer
Alexandre Fraichard Chief Operating Officer & Director
Robert Léon Director
Andre Tartar Director
Sector and Competitors
1st jan.Capi. (M$)
GENOWAY31.94%43
MODERNA, INC.305.22%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.41.30%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-9.18%28 939